Successful induction of remission with azacitidine, venetoclax, and dasatinib followed by allogeneic hematopoietic stem cell transplantation in a patient with Philadelphia chromosome-positive mixed phenotype acute leukemia (B/myeloid): a case report
Background Philadelphia chromosome-positive mixed phenotype acute leukemia (Ph+ MPAL) is a rare and aggressive hematologic malignancy. The incorporation of tyrosine kinase inhibitors (TKIs) into acute lymphoblastic leukemia (ALL)-like regimens has improved survival for Ph+ MPAL. However, the benefit of ALL-like chemoth...